4.4 Article

American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee

Journal

ARTHRITIS CARE & RESEARCH
Volume 64, Issue 4, Pages 465-474

Publisher

WILEY
DOI: 10.1002/acr.21596

Keywords

-

Categories

Funding

  1. ACR
  2. Abbott Laboratories
  3. Amgen
  4. AstraZeneca
  5. Bayer Health Care
  6. Bioiberica
  7. Bristol-Myers Squibb
  8. CombinatoRx
  9. Covidien
  10. Eli Lilly
  11. Genentech
  12. GlaxoSmithKline
  13. Hoffman-La Roche
  14. Merck
  15. Merck Serono International
  16. NicOx
  17. Novartis
  18. Pfizer
  19. Pozen
  20. Rand Corporation
  21. Sanofi-Aventis
  22. Smith Nephew
  23. Stryker Biotech
  24. TransPharma Medical
  25. NIH
  26. UCB
  27. Ferring
  28. Rotta
  29. Endo
  30. Lilly
  31. Schering
  32. Abbott
  33. Almirall
  34. Aventis
  35. Berlex
  36. Biomatrix
  37. Caduceus Group
  38. Centocor
  39. Chelsea
  40. Dimedix
  41. Dimethaid
  42. Glaxo-Welcome
  43. Hoechst Marion Roussel
  44. Immunomedics
  45. Innovus
  46. Johnson Johnson
  47. Larvol
  48. Lilly Research
  49. Medicine Group
  50. Medicus
  51. Merck Frosst
  52. Novopharm
  53. Ortho McNeil
  54. Pennside
  55. Roche
  56. Sandoz
  57. Scios
  58. Searle
  59. Teva Pharmaceuticals
  60. Wyeth Ayerst
  61. Cigna
  62. Genzyme
  63. IDRC
  64. Parke-Davis
  65. Rhone-Poulenc
  66. Smithkline Beecham

Ask authors/readers for more resources

Objective To update the American College of Rheumatology (ACR) 2000 recommendations for hip and knee osteoarthritis (OA) and develop new recommendations for hand OA. Methods. A list of pharmacologic and nonpharmacologic modalities commonly used to manage knee, hip, and hand OA as well as clinical scenarios representing patients with symptomatic hand, hip, and knee OA were generated. Systematic evidence- based literature reviews were conducted by a working group at the Institute of Population Health, University of Ottawa, and updated by ACR staff to include additions to bibliographic databases through December 31, 2010. The Grading of Recommendations Assessment, Development and Evaluation approach, a formal process to rate scientific evidence and to develop recommendations that are as evidence based as possible, was used by a Technical Expert Panel comprised of various stakeholders to formulate the recommendations for the use of nonpharmacologic and pharmacologic modalities for OA of the hand, hip, and knee. Results. Both strong and conditional recommendations were made for OA management. Modalities conditionally recommended for the management of hand OA include instruction in joint protection techniques, provision of assistive devices, use of thermal modalities and trapeziometacarpal joint splints, and use of oral and topical nonsteroidal antiinflammatory drugs (NSAIDs), tramadol, and topical capsaicin. Nonpharmacologic modalities strongly recommended for the management of knee OA were aerobic, aquatic, and/ or resistance exercises as well as weight loss for overweight patients. Nonpharmacologic modalities conditionally recommended for knee OA included medial wedge insoles for valgus knee OA, subtalar strapped lateral insoles for varus knee OA, medially directed patellar taping, manual therapy, walking aids, thermal agents, tai chi, selfmanagement programs, and psychosocial interventions. Pharmacologic modalities conditionally recommended for the initial management of patients with knee OA included acetaminophen, oral and topical NSAIDs, tramadol, and intraarticular corticosteroid injections; intraarticular hyaluronate injections, duloxetine, and opioids were conditionally recommended in patients who had an inadequate response to initial therapy. Opioid analgesics were strongly recommended in patients who were either not willing to undergo or had contraindications for total joint arthroplasty after having failed medical therapy. Recommendations for hip OA were similar to those for the management of knee OA. Conclusion. These recommendations are based on the consensus judgment of clinical experts from a wide range of disciplines, informed by available evidence, balancing the benefits and harms of both nonpharmacologic and pharmacologic modalities, and incorporating their preferences and values. It is hoped that these recommendations will be utilized by health care providers involved in the management of patients with OA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available